

References

S-140

1. Tan C, Chew M, Kai-Hung L, et al. Factors affecting visual outcome of myopic choroidal neovascularization treated with verteporfin photodynamic therapy. *Int J Ophthalmol.* 2013; 6(3):327-330.
2. Farinha CL, Baltar AS, Nunes SG, et al. Choroidal thickness after treatment for myopic choroidal neovascularization. *Eur J Ophthalmol.* 2013;23(6):887-898.
3. Lim SH, Chang W, Sagong M. Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy. *Eye.* 2013; 27(3):353-362.
4. Photodynamic Therapy for age-related macular degeneration. WebMD. Accessed November 19, 2014.
5. Alkin Z, Perente I, Ozkaya A, et al. Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. *Clin Ophthalmol.* 2014;8:685-690.
6. National Cancer Institute. Intraocular (uveal) melanoma treatment (PDQ®). NCI. 2014. Accessed 12/02/2014.
7. Wang W, He M, Zhang X. Combined intravitreal anti-VEGF and photodynamic therapy versus photodynamic monotherapy for polypoidal choroidal vasculopathy: A systematic review and meta-analysis of comparative studies. *PLoS ONE.* 2014;9(10):e110667.
8. Liegl R, Ulbig MW. Central serous chorioretinopathy. *Ophthalmologica.* 2014;232:65-76.
9. Erikitola OC1, Crosby-Nwaobi R1, Lotery AJ2, Sivaprasad S1. Photodynamic therapy for central serous chorioretinopathy. *Eye.* 2014;28(8):944-57.
10. Liu C, Chen L, Tsai SH, et al. Half-dose verteporfin combined with half-fluence photodynamic therapy for chronic central serous chorioretinopathy. *Journal of Ocular Pharmacology and Therapeutics.* 2014;30(5):400-405.
11. Claxton L, Malcolm B, Taylor M, et al. Ranibizumab, verteporfin photodynamic therapy or observation for the treatment of myopic choroidal neovascularization: cost effectiveness in the UK. *Drugs Aging.* 2014;31(11):837-848.
12. American Academy of Ophthalmology Retina/Vitrous Panel. Preferred Practice Pattern® Guidelines. Age-related macular degeneration. San Francisco, CA. 2015.
13. Ma J, Meng N, Xu X, Zhou F. System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy. *Acta Ophthalmologica.* 2014;92(8):e594-e601.
14. Hu Z, Oleinick N, Hamblin M. Photodynamic therapy as an emerging treatment modality for cancer and non-cancer diseases. *J Anal Bioanal Tech.* 2014;S1:e001.doi:10.4172/2155-9872.S1.
15. Salehi M, Wenick As, Law HA, Evans JR, Gehlbach P. interventions for central serous chorioretinopathy: a network meta-analysis. *Cochrane Database Syus Rev.* 2015;22(12)CD01184d1.

16. Atik A, Hu Y, Yu H, et al. Changes in macular sensitivity after hal-dose photodynamic therapy for chronic central serous chorioretinopathy. *BMC Ophthalmology*. 2017;17:140.
17. Cheng CK, Chang CK, Peng CH. Comparison of photodynamic therapy using half-dose of verteporfin or half-fluence of laser light for the treatment of CCSC. *Retina*. 2017;37(2):325-333.
18. Fabian I, Stacey A, Papastefanou V, et al. Primary photodynamic therapy with verteporfin for small pigmented posterior pole choroidal melanoma. *Eye*. 2017;31:519-528.
19. Rundle P. Photodynamic therapy for eye cancer. *Biomedicines*. 2017;5:69.
20. Blasi M, Pagliara M, Lanza A, et al. Photodynamic therapy in ocular oncology. *Biomedicines*. 2018;6:17.